TACC3 and glioma: A specific FGFR inhibitor, JNJ-42756493, exhibited tolerable toxicity and significant anti-tumor activity in preclinical models of FGFR3-TACC3-positive gliomas, providing preliminary evidence of sensitivity for clinical trials (Di Stefano et al., 2015).